MYH7

MyoKardia Doses First Patient in Phase 2 Clinical Trial of Danicamtiv in Genetic Dilated Cardiomyopathy

Retrieved on: 
Wednesday, September 9, 2020

Danicamtiv is MyoKardias most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.

Key Points: 
  • Danicamtiv is MyoKardias most advanced clinical candidate being developed for the treatment of genetic dilated cardiomyopathy (DCM) and other targeted populations with conditions of reduced systolic function.
  • MyoKardias Phase 2 study of danicamtiv will enroll patients with DCM with documented genetic variants of MYH7 or titin.
  • MyoKardia intends to advance danicamtiv in further clinical studies to characterize clinical benefit, starting with a Phase 2 clinical trial in patients with genetic dilated cardiomyopathy.
  • Voors, et al, European Journal of Heart Failure, 2020
    Sinagra, et al, (editors), Dilated Cardiomyopathy: From Genetics to Clinical Management, Springer 2019
    Lund et al.